Main Article Content


The objective of an exit survey is to improve and authorize a rapid and efficient “liquid chromatography-tandem mass spectrometry (LC-MS/MS)” technique for examination of Niraparib in plasma samples. Niraparib was separated utilizing “X-Bridge C18, 50 x 4.6 mm”, 5 µm column with MP composed of 10 mM Methanol &Ammonium format in a proportion of (20:80 v/v). MRM positive mode is utilized to identify the Niraparib at 321.5®195.4. The approach illustrates sinter &intra- day precision surrounded by0.7 to 2.0 and 0.7 to 2.7 % and accuracy within 101.4-102.4 & 99.5-104.8 %. Germline mutations in BRCA1 and 2, two genes associated with mechanisms of DNA reparation impairment, are appeared to be connected with breast incidence and malignant ovarian growth, both irregular& familiar. PARP is a group of enzymes engaged with BER system. The presentation of PARP inhibitors in patients with BRCA-transformed ovarian malignant growth is associated with the synthetic lethality concept. Niraparib (NR) is an inhibitor of "poly (ADP-ribose) polymerase (PARP) enzymes", PARP-1, and PARP-2 performs a character in DNA restoration. We observed such vast numbers of challenges with the revealed strategies regarding stability &reproducibility for long-run analysis. It is crucial to building up the tremendous bioanalytical method with appropriate Deuterated or analog-based internal standard in terms of reproducibility and matrix effect.


Niraparib Liquid ChromatographyTandem Mass Spectrometry Liquid Liquid Extractions base excision repair (BER) mobile phase (MP) Limit of detection and quantification (LOD and LOQ)

Article Details

How to Cite
Ravishankar, Ramya, Jaffar Hussain, & Virendra Kumar. (2020). A survey on improving validation in plasma samples by niraparib and LC-MS/MS methods. International Journal of Research in Pharmaceutical Sciences, 11(SPL4), 276-281.